Form D · Biotechnology
Better Therapeutics, Inc.
San Francisco, CA · CIK 0001832415
Offering snapshot reported Jan 23, 2024 · SEC filing
- Reported sold
- $250K Offering amount: $250K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 9, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 23, 2024 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Aug 11, 2023 | Initial | $2,114,998 | No comparison | 10 | SEC filing |
| Apr 21, 2023 | Initial | $6,500,001 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-503221
Private placement of 1,471,453 shares of common stock at a price of $0.1699 per share.
Source: Form D, filed Jan 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Andrew Armanino | Director |
| Mark Berman | Executive |
| Richard Carmona | Director |
| Elder Granger | Director |
| Mark Heinen | Executive |
| Frank Karbe | Director, Executive |
| Risa Lavizzo Mourey | Director |
| Geoffrey Parker | Director |
| David Perry | Director, Executive |
| Kristin Wynholds | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
548 Market St. #49404
San Francisco, CA, 94101
San Francisco, CA, 94101